Updated COVID-19 Information as of April 20, 2021

Mary Madison, RN, RAC-CT, CDP
Clinical Consultant – Briggs Healthcare

FDA Revoked Emergency Use Authorization for Monoclonal Antibody Bamlanivimab on Friday, April 16, 2021.  The U.S. Food and Drug Administration revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients. Based on its ongoing analysis of emerging scientific data, specifically the sustained increase of SARS-CoV-2 viral variants that are resistant to bamlanivimab alone resulting in the increased risk for treatment failure, the FDA has determined that the known and potential benefits of bamlanivimab, when administered alone, no longer outweigh the known and potential risks for its authorized use. Therefore, the agency determined that the criteria for issuance of an authorization are no longer met and has revoked the EUA.

Newly posted materials from NHSNfor LTCFs:

CDC has posted updates to these vaccination websites:

One thought on “Updated COVID-19 Information as of April 20, 2021

Comments are closed.